Connect
MJA
MJA

Dabigatran — neurosurgical anathema?

Piers A W Thomas, Nicholas B Schaerf and Jeffrey V Rosenfeld
Med J Aust 2013; 199 (4): 238-240. || doi: 10.5694/mja13.10552
Published online: 19 August 2013

To the Editor: We welcome the articles by Eikelboom and Hankey1 and Attia and Pearce2 about the use of dabigatran as an alternative to warfarin for prevention of embolic stroke. While it is encouraging that new, effective, anticoagulant agents have been added to the anticoagulant pharmacopoeia, we wish to raise specific concerns about the management of intracranial haemorrhage in patients treated with dabigatran.

  • Piers A W Thomas1
  • Nicholas B Schaerf1
  • Jeffrey V Rosenfeld1,2

  • 1 Department of Neurosurgery, Alfred Hospital, Melbourne, VIC.
  • 2 Department of Surgery, Monash University, Melbourne, VIC.

Correspondence: drpiersthomas@gmail.com

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.